The Experts below are selected from a list of 195 Experts worldwide ranked by ideXlab platform

B. B. Goswami - One of the best experts on this subject based on the ideXlab platform.

  • Studies on the intravenous pharmacokinetics in rabbit and in vitro protein binding of two new salts of Erythromycin: Erythromycin maltobionate and Erythromycin fumarate.
    Biopharmaceutics & Drug Disposition, 1992
    Co-Authors: S. K. Basu, P. K. Manna, B. B. Goswami
    Abstract:

    Pharmacokinetics in rabbits following intravenous administration and in vitro protein binding were studied for two new salts of Erythromycin (Erythromycin maltobionate and Erythromycin fumarate). Serum Erythromycin levels following intravenous injection were described by two compartment model kinetics, and values for the distribution volume of the central compartment, the peripheral compartment and overall distribution volume were calculated. The elimination half-lives of Erythromycins in serum were 83 min, 168 min, and 103 min for Erythromycin maltobionate, Erythromycin fumarate, and Erythromycin Lactobionate (reference standard), respectively. The Erythromycin salts were highly (c. 90 per cent) protein bound, but the binding was found to be reversible. Differences in the pharmacokinetic parameters after administration of equivalent doses of the salts, indicate possible variation in efficacies of different salts.

Jerry L. Bauman - One of the best experts on this subject based on the ideXlab platform.

  • qt interval prolongation and torsades de pointes due to Erythromycin Lactobionate
    Pharmacotherapy, 1995
    Co-Authors: Kristin C. Oberg, Jerry L. Bauman
    Abstract:

    Study Objectives. To discern the frequency of torsades de pointes and QT prolongation in patients receiving intravenous Erythromycin Lactobionate; to examine the degree of QT prolongation and QT dispersion due to intravenous Erythromycin in a typical clinical setting; and to identify any concurrent factors that might predispose patients to excessive QT prolongation or torsades de pointes while receiving intravenous Erythromycin. Design. Retrospective cohort trial. Setting. A university teaching hospital. Patients. All inpatients who received intravenous Erythromycin Lactobionate during a 1-year period. Measurements and Main Results. The records of 278 consecutive patients were analyzed, of whom 49 had 12-lead electrocardiograms while receiving and not receiving Erythromycin. The dosages of Erythromycin ranged from 18–83 (42 pL 18) mg/kg/day. Of the 49 patients, the baseline QTc was 432 ± 39 msec, compared with 483 ± 62 msec during Erythromycin therapy (p<0.01). In 30 of 49 patients with heart disease, the increase in QTc due to Erythromycin was 15 ± 11%, compared with 8.6 ± 10% in the 19 patients without heart disease (p<0.05). The degree of QTc dispersion was 34 ± 16 msec at baseline, compared with 80 ± 35 msec with Erythromycin (p<0.01). Overall, 19 (39%) of 49 patients had a moderate to severe delay in ventricular repolarization (QTc ≥ 500 msec). Of the 278 patients prescribed intravenous Erythromycin over the year, it caused torsades de pointes in just one (≤ 0.4%). Conclusion. Erythromycin Lactobionate-induced torsades de pointes is rare, although QT prolongation is common. Some patients may be at risk for suffering torsades de pointes due to this agent, particularly if heart disease or other factors that may further delay ventricular repolarization are present.

  • QT Interval Prolongation and Torsades de Pointes Due to Erythromycin Lactobionate
    Pharmacotherapy, 1995
    Co-Authors: Kristin C. Oberg, Jerry L. Bauman
    Abstract:

    Study Objectives. To discern the frequency of torsades de pointes and QT prolongation in patients receiving intravenous Erythromycin Lactobionate; to examine the degree of QT prolongation and QT dispersion due to intravenous Erythromycin in a typical clinical setting; and to identify any concurrent factors that might predispose patients to excessive QT prolongation or torsades de pointes while receiving intravenous Erythromycin. Design. Retrospective cohort trial. Setting. A university teaching hospital. Patients. All inpatients who received intravenous Erythromycin Lactobionate during a 1-year period. Measurements and Main Results. The records of 278 consecutive patients were analyzed, of whom 49 had 12-lead electrocardiograms while receiving and not receiving Erythromycin. The dosages of Erythromycin ranged from 18–83 (42 pL 18) mg/kg/day. Of the 49 patients, the baseline QTc was 432 ± 39 msec, compared with 483 ± 62 msec during Erythromycin therapy (p

S. K. Basu - One of the best experts on this subject based on the ideXlab platform.

  • Studies on the intravenous pharmacokinetics in rabbit and in vitro protein binding of two new salts of Erythromycin: Erythromycin maltobionate and Erythromycin fumarate.
    Biopharmaceutics & Drug Disposition, 1992
    Co-Authors: S. K. Basu, P. K. Manna, B. B. Goswami
    Abstract:

    Pharmacokinetics in rabbits following intravenous administration and in vitro protein binding were studied for two new salts of Erythromycin (Erythromycin maltobionate and Erythromycin fumarate). Serum Erythromycin levels following intravenous injection were described by two compartment model kinetics, and values for the distribution volume of the central compartment, the peripheral compartment and overall distribution volume were calculated. The elimination half-lives of Erythromycins in serum were 83 min, 168 min, and 103 min for Erythromycin maltobionate, Erythromycin fumarate, and Erythromycin Lactobionate (reference standard), respectively. The Erythromycin salts were highly (c. 90 per cent) protein bound, but the binding was found to be reversible. Differences in the pharmacokinetic parameters after administration of equivalent doses of the salts, indicate possible variation in efficacies of different salts.

Kristin C. Oberg - One of the best experts on this subject based on the ideXlab platform.

  • qt interval prolongation and torsades de pointes due to Erythromycin Lactobionate
    Pharmacotherapy, 1995
    Co-Authors: Kristin C. Oberg, Jerry L. Bauman
    Abstract:

    Study Objectives. To discern the frequency of torsades de pointes and QT prolongation in patients receiving intravenous Erythromycin Lactobionate; to examine the degree of QT prolongation and QT dispersion due to intravenous Erythromycin in a typical clinical setting; and to identify any concurrent factors that might predispose patients to excessive QT prolongation or torsades de pointes while receiving intravenous Erythromycin. Design. Retrospective cohort trial. Setting. A university teaching hospital. Patients. All inpatients who received intravenous Erythromycin Lactobionate during a 1-year period. Measurements and Main Results. The records of 278 consecutive patients were analyzed, of whom 49 had 12-lead electrocardiograms while receiving and not receiving Erythromycin. The dosages of Erythromycin ranged from 18–83 (42 pL 18) mg/kg/day. Of the 49 patients, the baseline QTc was 432 ± 39 msec, compared with 483 ± 62 msec during Erythromycin therapy (p<0.01). In 30 of 49 patients with heart disease, the increase in QTc due to Erythromycin was 15 ± 11%, compared with 8.6 ± 10% in the 19 patients without heart disease (p<0.05). The degree of QTc dispersion was 34 ± 16 msec at baseline, compared with 80 ± 35 msec with Erythromycin (p<0.01). Overall, 19 (39%) of 49 patients had a moderate to severe delay in ventricular repolarization (QTc ≥ 500 msec). Of the 278 patients prescribed intravenous Erythromycin over the year, it caused torsades de pointes in just one (≤ 0.4%). Conclusion. Erythromycin Lactobionate-induced torsades de pointes is rare, although QT prolongation is common. Some patients may be at risk for suffering torsades de pointes due to this agent, particularly if heart disease or other factors that may further delay ventricular repolarization are present.

  • QT Interval Prolongation and Torsades de Pointes Due to Erythromycin Lactobionate
    Pharmacotherapy, 1995
    Co-Authors: Kristin C. Oberg, Jerry L. Bauman
    Abstract:

    Study Objectives. To discern the frequency of torsades de pointes and QT prolongation in patients receiving intravenous Erythromycin Lactobionate; to examine the degree of QT prolongation and QT dispersion due to intravenous Erythromycin in a typical clinical setting; and to identify any concurrent factors that might predispose patients to excessive QT prolongation or torsades de pointes while receiving intravenous Erythromycin. Design. Retrospective cohort trial. Setting. A university teaching hospital. Patients. All inpatients who received intravenous Erythromycin Lactobionate during a 1-year period. Measurements and Main Results. The records of 278 consecutive patients were analyzed, of whom 49 had 12-lead electrocardiograms while receiving and not receiving Erythromycin. The dosages of Erythromycin ranged from 18–83 (42 pL 18) mg/kg/day. Of the 49 patients, the baseline QTc was 432 ± 39 msec, compared with 483 ± 62 msec during Erythromycin therapy (p

James Toouli - One of the best experts on this subject based on the ideXlab platform.

  • Erythromycin and motilin stimulate sphincter of Oddi motility and inhibit trans-sphincteric flow in the Australian possum.
    Naunyn-schmiedebergs Archives of Pharmacology, 1992
    Co-Authors: Gino T.p. Saccone, Anders Thune, John R. Harvey, Robert A. Baker, James Toouli
    Abstract:

    The actions of Erythromycin Lactobionate and porcine motilin on trans-sphincteric flow and simultaneous sphincter of Oddi motility were studied in 15 anaesthetized Australian Brush-tailed possums (Trichosurus vulpecula). Erythromycin (25–200 μg/kg) and motilin (25–200 ng/kg) were administered as graded doses by close intraarterial injection. Trans-sphincteric flow was measured as inflow and outflow. Both motilin and Erythromycin decreased trans-sphincteric inflow (both P

  • Motilin and Erythromycin enhance the in vitro contractile activity of the sphincter of Oddi of the Australian brush-tailed possum.
    Naunyn-Schmiedeberg's archives of pharmacology, 1992
    Co-Authors: Robert A. Baker, Gino T.p. Saccone, Anders Thune, David Costi, James Toouli
    Abstract:

    Erythromycin has been shown to interact with gastrointestinal smooth muscle in a similar manner to motilin, and has been postulated as a motilin receptor agonist. We report that in isolated preparations from the biliary tract of thirty one Australian Brush-tailed Possums (Trichosurus vulpecula) Erythromycin acts in a similar manner to motilin. In all muscle strips from the sphincter of Oddi, prepared in both the circular and longitudinal orientation, both synthetic porcine motilin (10−10 M − 10−6 M) and Erythromycin (Lactobionate) (10−8 M − 10−4 M) stimulated contractile activity in a concentration dependant manner, via a direct effect on the smooth muscle (the response was unaffected by tetrodotoxin, omega conotoxin GVIA or atropine). In strips prepared from the gallbladder neither agonist affected the contractile activity in 7 of 8 animals.